Abstract
Multi-regional clinical trials (MRCTs) have become common practice for drug development and global registration. Once overall significance is established, demonstrating regional consistency is critical for local health authorities. Methods for evaluating such consistency and calculating regional sample sizes have been proposed based on the fixed effects model using various criteria. To better account for the heterogeneity of treatment effects across regions, the random effects model naturally arises as a more effective alternative for both design and inference. In this paper, we present the design of the overall sample size along with regional sample fractions. We also provide the theoretical properties for assessing consistency probability using Method 1 of Ministry of Health, Labour and Welfare of Japan (MHLW), based on the empirical shrinkage estimator. The latter is then used to determine the regional sample size of interest. We elaborate on the applications to normal, binary, and survival endpoints in detail. Simulation studies show that the proposed method retains the consistency probability at the desired level. We illustrate the application using a real cardiovascular outcome trial in diabetes. An R package is provided for implementation.
| Original language | English |
|---|---|
| Article number | e70090 |
| Journal | Pharmaceutical Statistics |
| Volume | 25 |
| Issue number | 3 |
| DOIs | |
| State | Published - 1 May 2026 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- Bayesian shrinkage estimator
- MRCT
- consistency assessment
- random effects model
- regional sample size
Fingerprint
Dive into the research topics of 'Consistency Assessment and Regional Sample Size Calculation for MRCT Under Random Effects Model'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver